CEO: Henry Sicgnano President and COO
Headquarters: Clarence, New York
Investment Date: January 2011
APO Financing: $5,435,000
Trading Venue: NYSE Market (XXII)
22nd Century is a plant biotechnology company whose proprietary technology through genetic engineering and plant breeding allows (i) the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased and (ii) the levels of cannabinoids to be decreased or increased in addition to the cannabinoid profile being tailored.
22nd Century owns or is the exclusive licensee of 129 issued patents in 78 countries plus an additional 51 pending patent applications, and 22nd Century has co-exclusive rights to another 16 patent applications. Goodrich Tobacco Company, LLC, Botanical Genetics, LLC, and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century Group.